AREDS2type

AREDS2type refers to dietary supplement formulations designed to approximate the composition and intent of the AREDS2 trial for age-related macular degeneration (AMD). The term is not part of an official regulatory category but is used in ophthalmology literature and marketing to distinguish products that follow AREDS2 principles—namely, replacing beta-carotene with lutein and zeaxanthin, and often omitting other components that showed limited benefit.

Typical AREDS2type formulations include vitamin C (about 500 mg), vitamin E (about 400 IU), zinc (about 80 mg as zinc oxide) with copper (about 2 mg), along with lutein (about 10 mg) and zeaxanthin (about 2 mg). Beta-carotene is generally not included due to associations with lung cancer risk in smokers. Some products also include optional omega-3 fatty acids, though this was not required by AREDS2.

Rationale: AREDS2type products are intended for individuals at risk of progression from intermediate to advanced AMD or who have advanced AMD in one eye. They reflect evidence that lutein and zeaxanthin can replace beta-carotene without diminishing potential benefit, and that reducing beta-carotene-associated risks is advisable for smokers.

Limitations: AREDS2type supplements are not a cure for AMD and do not guarantee prevention of progression. Efficacy can vary, and high-dose zinc may cause adverse effects in some individuals. Users should consult healthcare providers, particularly if they have kidney disease, are pregnant, or smoke.